Drugs / magnesium valproate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03204500 | May 2016 → Apr 2019 | sporadic amyotrophic lateral sclerosis | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02446652 | Jan 2015 → Jul 2018 | cervical cancer | National Institute of Cancerology | Withdrawn | No outcome recorded |
| Phase 3 | NCT00532818 | Jul 2007 → Sep 2010 | cervical cancer | National Institute of Cancerology | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | magnesium valproate | “Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours” NCT02446652 ↗2“Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.” NCT03204500 ↗ |
| Route | Oral | “magnesium valproate at an oral dose of 40mg/Kg t.i.d.” NCT00532818 ↗ |